Boundless Bio Appoints New CMO, Director; CMO Departs

Ticker: BOLD · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1782303

Boundless Bio, INC. 8-K Filing Summary
FieldDetail
CompanyBoundless Bio, INC. (BOLD)
Form Type8-K
Filed DateOct 15, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: executive-change, board-change, personnel

TL;DR

Boundless Bio's CMO is out, new CMO and board member in. Big shakeup.

AI Summary

On October 11, 2024, Boundless Bio, Inc. announced changes to its executive team and board of directors. Dr. Peter Blume-Jensen has resigned as Chief Medical Officer and from the Board of Directors. Dr. Robert J. Cervera has been appointed as the new Chief Medical Officer. Additionally, Dr. David J. Earp has been appointed to the Board of Directors.

Why It Matters

This filing indicates significant leadership changes within Boundless Bio, including the departure of a key executive and the appointment of new leadership, which could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Leadership changes, especially the departure of a Chief Medical Officer, can signal internal challenges or strategic shifts, introducing uncertainty for investors.

Key Players & Entities

FAQ

Who has resigned from Boundless Bio, Inc. and in what capacities?

Dr. Peter Blume-Jensen has resigned as Chief Medical Officer and from the Board of Directors.

Who has been appointed as the new Chief Medical Officer?

Dr. Robert J. Cervera has been appointed as the new Chief Medical Officer.

Who has been appointed to the Board of Directors?

Dr. David J. Earp has been appointed to the Board of Directors.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is October 11, 2024.

What is the principal executive office address for Boundless Bio, Inc.?

The address of the Principal Executive Offices is 9880 Campus Point Drive, Suite 120, San Diego, California 92121.

Filing Stats: 851 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-10-15 08:00:09

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BOUNDLESS BIO, INC. Date: October 15, 2024 By: /s/ Jessica Oien Name: Jessica Oien Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing